Byron Padilla

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study

Andrew J.K. Östör, Filip Van den Bosch, Kim Papp et al. · Lara D. Veeken · 2022 · 30 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension

C. François, Cyndya A. Shibao, Italo Biaggioni et al. · Movement Disorders Clinical Practice · 2019 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

Kim Papp, Saskia de Vente, Jiewei Zeng et al. · Dermatology and Therapy · 2021 · 13 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

Andrew J.K. Östör, Ahmed M. Soliman, Kim Papp et al. · RMD Open · 2022 · 12 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

Lars Erik Kristensen, Mauro Waldemar Keiserman, Kim Papp et al. · Rheumatology and Therapy · 2024 · 12 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17